Product Images Donepezil Hydrochloride

This is a description of a medication package for Donepezil Hydrochloride tablets. The package contains 10 tablets, with each coated tablet having 10mg of Donepezil Hydrochloride. The usual dosage and precautions are available in the product insert. The website WWW.MAJORPHARMACEUTICALS.COM is provided for information. The tablets should be stored in a tightly sealed container and away from children. The package is not child-resistant and intended for institutional use only. It should be dispensed under the supervision of a pharmacist along with a patient information sheet. This medication is manufactured by Torrent Pharmaceuticals Ltd and is distributed by Major® Pharmaceuticals through Cardinal Health.*

Donepezil Hydrochloride Tablets is a medication distributed by Major Pharmaceuticals in a 10 tablet pack. Each tablet contains 5mg donepezil hydrochloride, USP. It's recommended to Store the tablets at 20° - 25° C (68 - 77° F); and it's only for Institutional Use. The tablet pack is not child-resistant, so it should be kept away from children. The medication should be dispensed in a tight, light-resistant container. There are more precise instructions and information available at www.majorpharmaceuticals.com which should be referred to before consuming the medication.*

This is a table that shows the ADAS-cog change from baseline after 6, 12 and 18 weeks of drug treatment. The drugs being compared are Donepezil Hydrochloride Tablets 10 mg/day, Donepezil Hydrochloride Tablets 5 mg/day, and Placebo. The table shows mean values for clinical improvement and clinical decline.*

The text describes a chart showing the cumulative percentage of patients with Alzheimer's disease and the change in their cognitive function (ADAS-cog) based on the dosage of Donepezil Hydrochloride (5mg and 10mg) or a placebo over a period of 10 months. The chart also shows the percentage of patients with no change in cognitive function.*

This text appears to be a chart or graph showing the effectiveness of three different treatments (BN Donepezil Hydrochloride Tablets 10 mg/day, Donepezil Hydrochloride Tablets 5 mg/day, and Placebo) for patients over a period of time. The chart appears to measure improvement, worsened symptoms, and no change using the CIBIC-plus rating system. However, without further context or a clear image, it is difficult to provide a more detailed description.*

The text is describing a chart that shows the cumulative percentage of patients for Donepezil Hydrochloride Tablets 10 mg/day and placebo. It also shows the change from baseline in SIB (Severe Impairment Battery) for the patients.*

The text describes a figure showing the time course of change in a score called ADCS-ADL-Severe for patients who completed 6 months of treatment. The figure has a graph with lines indicating clinical improvement or decline in the score over time, as well as a baseline and treatment with donepezil hydrochloride tablets (10mg/day) or placebo.*

The text describes a graph showing the cumulative percentage of patients, comparing the effectiveness of Donepezil Hydrochloride (10mg/day) tablets versus a placebo, in terms of ADCS-ADL change from the baseline. The graph ranges from -10% to 100%, with the percentage values shown on the Y-axis, and the ADCS-ADL change from the baseline values on the X-axis, ranging from +5 to -5.*